Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is ...
emjreviews.com11h
Neoadjuvant T-VEC Shows Promise for Difficult-to-Treat Basal Cell Carcinoma
T-VEC enables BCC resectability in 50% of cases, showing promise as a neoadjuvant therapy with mild side effects.
University of California19h
Breast cancer treatment advances with light-activated ‘smart bomb’
It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor ...
rsvplive3d
Emmerdale star shows off facial scar after cancer surgery and sends warning to fans
The actor, 54, had a procedure done to remove basal cell carcinoma from his face and is warning his fans to take care and ...
Hosted on MSN5d
Coco Gauff suffers fresh setback as she prepares for her Qatar Open showdown
Coco Gauff faces a fresh setback ahead of her Qatar Open debut, rebounding from an Australian Open upset while dealing with ...